HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.

AbstractBACKGROUND:
Antimitotic agents are essential components for curative therapy of pediatric acute leukemias and many solid tumors. Eribulin is a novel agent that differs from both Vinca alkaloids and taxanes in its mode of binding to tubulin polymers.
PROCEDURES:
Eribulin was tested against the PPTP in vitro cell line panel at concentrations from 0.1 nM to 1.0 μM and against the PPTP in vivo xenograft panels at a dose of 1 mg/kg (solid tumors) or 1.5 mg/kg (ALL models) using a q4dx3 schedule repeated at Day 21.
RESULTS:
In vitro eribulin demonstrated cytotoxic activity, with a median relative IC50 value of 0.27 nM, (range <0.1-14.8 nM). Eribulin was well tolerated in vivo, and all 43 xenograft models were considered evaluable for efficacy. Eribulin induced significant differences in event-free survival (EFS) distribution compared to control in 29 of 35 (83%) of the solid tumors and in 8 of 8 (100%) of the ALL xenografts. Objective responses were observed in 18 of 35 (51%) solid tumor xenografts. Complete responses (CR) or maintained CR were observed in panels of Wilms tumor, Ewing sarcoma, rhabdomyosarcoma, glioblastoma, and osteosarcoma xenografts. All eight ALL xenografts achieved CR or MCR.
CONCLUSIONS:
The high level of activity observed for eribulin against the PPTP preclinical models makes this an interesting agent to consider for pediatric evaluation. The activity pattern observed for eribulin in the solid tumor panels is equal or superior to that observed previously for vincristine.
AuthorsE Anders Kolb, Richard Gorlick, C Patrick Reynolds, Min H Kang, Hernan Carol, Richard Lock, Stephen T Keir, John M Maris, Catherine A Billups, Christopher Desjardins, Raushan T Kurmasheva, Peter J Houghton, Malcolm A Smith
JournalPediatric blood & cancer (Pediatr Blood Cancer) Vol. 60 Issue 8 Pg. 1325-32 (Aug 2013) ISSN: 1545-5017 [Electronic] United States
PMID23553917 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2013 Wiley Periodicals, Inc.
Chemical References
  • Furans
  • Ketones
  • Tubulin Modulators
  • eribulin
Topics
  • Animals
  • Cell Line, Tumor
  • Furans (pharmacology)
  • Humans
  • Ketones (pharmacology)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Mice, SCID
  • Neoplasms, Experimental (drug therapy, pathology)
  • Tubulin Modulators (pharmacology)
  • Xenograft Model Antitumor Assays (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: